Composition comprising a pulmonary surfactant and a TNF-derived peptide
View Patent ↗The invention relates to the combination of a pulmonary surfactant and a TNF-derived peptide and its use for the treatment of respiratory disease.
1. A pharmaceutical composition comprising:
a therapeutically effective amount of a pulmonary surfactant selected from the group consisting of CUROSURF®, SURVANTA®, ALVEOFACT®, SURFACTEN@, INFASURF®, BLES®, SINAPULTIDE® and a pulmonary surfactant comprising phospholipids and pulmonary surfactant protein, the pulmonary surfactant protein being selected from the group consisting of Surfactant Protein-B (SP-B), Surfactant Protein-C (SP-C) and LUSUPULTIDE (rSP-C (FF/I)); a therapeutically effective amount of a peptide consisting of the amino acids according to SEQ ID NO: 2 or the amino acids according to SEQ ID NO: 3 and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition according to claim 1 , comprising as a fixed combination:
a therapeutically effective amount of a pulmonary surfactant selected from the group consisting of CUROSURF®, SURVANTA®, ALVEOFACT®, SURFACTEN®, INFASURF®, BLES®, SINAPULTIDE® and a pulmonary surfactant comprising phospholipids and pulmonary surfactant protein, the pulmonary surfactant protein being selected from the group consisting of Surfactant Protein-B (SP-B), Surfactant Protein-C (SP-C) and LUSUPULTIDE (rSP-C (FF/I)); and a therapeutically effective amount of a peptide consisting of the amino acids according to SEQ ID NO: 2 or the amino acids according to SEQ ID NO: 3.
3. The pharmaceutical composition according to claim 2 , which is a powder formulation.
4. The pharmaceutical composition according to claim 2 , which is a liquid formulation.
5. The pharmaceutical composition according to claim 2 , which is a fixed pharmaceutical composition for intratracheal or intrabronchial instillation.
6. The pharmaceutical composition according to claim 2 , which is a fixed pharmaceutical composition for inhalation.
7. The pharmaceutical composition according to claim 1 , comprising as a free combination:
a therapeutically effective amount of a pulmonary surfactant selected from the group consisting of CUROSURF®, SURVANTA®, ALVEOFACT®, SURFACTEN®, INFASURF®, BLES®, SINAPULTIDE® and a pulmonary surfactant comprising phospholipids and pulmonary surfactant protein, the pulmonary surfactant protein being selected from the group consisting of Surfactant Protein-B (SP-B), Surfactant Protein-C (SP-C) and LUSUPULTIDE (rSP-C (FF/I)); and a therapeutically effective amount of a peptide consisting of the amino acids according to SEQ ID NO: 2 or the amino acids according to SEQ ID NO: 3.
8. The pharmaceutical composition according to claim 7 , wherein the pulmonary surfactant and the peptide are in a liquid form.
9. The pharmaceutical composition according to claim 7 , wherein the pulmonary surfactant and the peptide are in a powder form.
10. The pharmaceutical composition according to claim 7 , which is a free pharmaceutical composition for intratracheal or intrabronchial instillation.
11. The pharmaceutical composition according to claim 7 , which is a free pharmaceutical composition for inhalation.
12. The pharmaceutical composition according to claim 1 , wherein the peptide consists of the amino acids according to SEQ ID NO: 2.
13. The pharmaceutical composition according to claim 1 , wherein the peptide consists of the amino acids according to SEQ ID NO: 3.
14. The pharmaceutical composition according to claim 1 , wherein the peptide is synthetic.
15. The pharmaceutical composition according to claim 1 , wherein the peptide is circularized.
16. The pharmaceutical composition according to claim 1 , wherein the pulmonary surfactant is selected from the group consisting of CUROSURF®, SURVANTA®, ALVEOFACT®, SURFACTEN®, INFASURF®, SINAPULTIDE® and a pulmonary surfactant comprising phospholipids and pulmonary surfactant protein, the pulmonary surfactant protein being selected from the group consisting of SP-B, SP-C and rSP-C (FF/I).
17. The pharmaceutical composition according to claim 1 , wherein the pulmonary surfactant comprises phospholipids and rSP-C (FF/I).
18. The pharmaceutical composition according to claim 1 , wherein the pulmonary surfactant comprises 80 to 95% by weight of phospholipids, 0.5 to 3.0% by weight of pulmonary surfactant proteins, 3 to 15% by weight of fatty acid, and 0 to 3% by weight of calcium chloride.
19. The pharmaceutical composition according to claim 1 , wherein the pulmonary surfactant is selected from the group consisting of CUROSURF®, SURVANTA®, ALVEOFACT®, SURFACTEN®, and INFASURF®.